Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
February 05 2024 - 4:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE
13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2024
Commission File Number: 001-41661
JIN MEDICAL INTERNATIONAL LTD.
(Exact name of registrant as specified in its charter)
No. 33 Lingxiang Road, Wujin District
Changzhou City, Jiangsu Province
People’s Republic of China
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
INFORMATION CONTAINED IN THIS CURRENT REPORT ON
FORM 6-K
Jin Medical International Ltd. (the “Company”),
today announced that following approval by shareholders by way of an ordinary resolution at the extraordinary general meeting of the Company
held at 9.30 a.m. Beijing Time on January 30, 2024 (8.30 p.m. Eastern Time on January 29, 2024), its Board of Directors (the “Board”)
has determined to, effective on February 8, 2024, subdivide each of the issued and unissued ordinary shares with a par value of US$0.001
each in the capital of the Company into twenty (20) ordinary shares with a par value of US$0.00005 each (the “Subdivision”),
such that, following the Subdivision, the authorized share capital of the Company is US$50,000 divided into 1,000,000,000 shares
with a par value of US$0.00005 each.
When the Subdivision becomes effective, every one (1)
issued and authorized ordinary share of par value US$0.001 each will be divided into twenty (20) ordinary shares with a par value
of US$0.00005 each.
No fractional shares will be issued in connection with
the Subdivision. Shareholders may obtain instructions from the Company's transfer agent, Transhare Corporation, as to how to exchange
existing share certificates for new certificates representing the new shares in connection with the Subdivision.
SIGNATURES
Pursuant to the requirements of the Securities and
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
JIN MEDICAL INTERNATIONAL LTD. |
| |
|
|
| Date: February 5, 2024 |
By: |
/s/ Erqi Wang |
| |
|
Erqi Wang |
| |
|
Chief Executive Officer |
Jin Medical (NASDAQ:ZJYL)
Historical Stock Chart
From Apr 2024 to May 2024
Jin Medical (NASDAQ:ZJYL)
Historical Stock Chart
From May 2023 to May 2024
